Radioligand therapy for HER2-positive cancers enters human trials for the first time
Medical Xpress - medical research advances and health news [Uno…
June 25, 2026
The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial evaluating a novel radioligand therapy for HER2-positive cancers, including certain types of breast cancer.
Discussion in the ATmosphere